Skip to main content
. Author manuscript; available in PMC: 2012 Jan 13.
Published in final edited form as: J Neurosci. 2011 Jul 13;31(28):10347–10358. doi: 10.1523/JNEUROSCI.1470-11.2011

Table 1.

Experimental Groups and Testing Sequence

Group N Treatment Interval 1 Test 1 Interval 2 Test 2
1 78 VEH, MPH, FLX, or MPH+FLX 24-h Conditioned place preference X X
2 30 VEH, MPH, FLX, or MPH+FLX 24-h Elevated plus-maze 2-months Forced swim test
3 30 VEH, MPH, FLX, or MPH+FLX 24-h Forced swim test X X
4 32 VEH, MPH, FLX, or MPH+FLX 24-h Polymerase chain reaction X X
5 77 VEH, MPH, FLX, or MPH+FLX 2-months Conditioned place preference X X
6 40 VEH, MPH, FLX, or MPH+FLX 2-months Sucrose Preference 48 h Elevated plus-maze
7 32 VEH, MPH, FLX, or MPH+FLX 2-months Polymerase chain reaction + Western Blot X X
8 47 VEH, MPH, FLX, or MPH+FLX 2-months Viral Surgery 3 days Forced swim test

VEH: 0.9% sterile saline, MPH: methylphenidate (2.0 mg/kg), FLX: fluoxetine (2.5 mg/kg), MPH+FLX: methylphenidate and fluoxetine (2.0 and 2.5 mg/kg, respectively).